EMERYVILLE, Calif., Feb. 6, 2025
/PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a
commercial stage biopharmaceutical company developing and
commercializing innovative vaccines, will report fourth quarter and
full year 2024 financial results on Thursday, February 20, 2025, after the U.S.
financial markets close.
Dynavax will host a conference call and live audio webcast on
Thursday, February 20, 2025, at
4:30 p.m. ET/1:30 p.m. PT.
The live audio webcast may be accessed through the "Events &
Presentations" page on the "Investors" section of the Company's
website
at https://investors.dynavax.com/events-presentations. A
replay of the webcast will be available for 30 days following the
live event.
To dial into the call, participants will need to register for
the call using the caller registration link. It is recommended
that participants dial into the conference call or log into the
webcast approximately 10 minutes prior to the call.
About Dynavax
Dynavax is a commercial-stage
biopharmaceutical company developing and commercializing innovative
vaccines to help protect the world against infectious diseases. The
Company has two commercial products, HEPLISAV-B® vaccine
[Hepatitis B Vaccine (Recombinant), Adjuvanted], which is approved
in the U.S., the European Union and Great
Britain for the prevention of infection caused by all known
subtypes of hepatitis B virus in adults 18 years of age and older,
and CpG 1018® adjuvant, currently used in HEPLISAV-B and
multiple adjuvanted COVID-19 vaccines. For more information about
our marketed products and development pipeline, visit
www.dynavax.com.
For Investors/Media:
Paul
Cox
pcox@dynavax.com
510-665-0499
Nicole Arndt
narndt@dynavax.com
510-665-7264
View original content to download
multimedia:https://www.prnewswire.com/news-releases/dynavax-to-report-fourth-quarter-and-full-year-2024-financial-results-and-host-conference-call-on-february-20-2025-302370741.html
SOURCE Dynavax Technologies
